Evidence map›Paper›PMID 31386058›Full record

ReviewNeuro-oncology practice2016

Prevalence of changes in personality and behavior in adult glioma patients: a systematic review.

Hanneke Zwinkels, Linda Dirven, Thomas Vissers, Esther J J Habets, Maaike J Vos, Jaap C Reijneveld, Martin J van den Bent, Martin J B Taphoorn

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Defining the symptoms of personality and behaviour changes in brain tumour patients and their impact on caregivers.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Factors associated with psychological distress in caregivers of patients with malignant gliomas.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hanneke ZwinkelsMedical Center Haaglanden, Department of Neurology, Lijnbaan 32, 2512 VK The Hague, PO BOX 432, 2501 CK, The Hague, The Netherlands (H.Z., E.J.J.H., M.J.V., M.J.B.T.); Medical Center Haaglanden, Landsteiner Institute, Lijnbaan 32, 2512 VK The Hague, PO BOX 432, 2501 CK, The Hague, The Netherlands (T.V.); Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333ZA Leiden, The Netherlands (L.D., M.J.B.T.); Department of Neurology, VU Medical Center, de Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands (J.C.R.); Amsterdam Medical Center, Department of Neurology, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands (J.C.R.); Department of Neuro-oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands (M.J.v.d.B.).
Linda DirvenMedical Center Haaglanden, Department of Neurology, Lijnbaan 32, 2512 VK The Hague, PO BOX 432, 2501 CK, The Hague, The Netherlands (H.Z., E.J.J.H., M.J.V., M.J.B.T.); Medical Center Haaglanden, Landsteiner Institute, Lijnbaan 32, 2512 VK The Hague, PO BOX 432, 2501 CK, The Hague, The Netherlands (T.V.); Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333ZA Leiden, The Netherlands (L.D., M.J.B.T.); Department of Neurology, VU Medical Center, de Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands (J.C.R.); Amsterdam Medical Center, Department of Neurology, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands (J.C.R.); Department of Neuro-oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands (M.J.v.d.B.).
Thomas VissersMedical Center Haaglanden, Department of Neurology, Lijnbaan 32, 2512 VK The Hague, PO BOX 432, 2501 CK, The Hague, The Netherlands (H.Z., E.J.J.H., M.J.V., M.J.B.T.); Medical Center Haaglanden, Landsteiner Institute, Lijnbaan 32, 2512 VK The Hague, PO BOX 432, 2501 CK, The Hague, The Netherlands (T.V.); Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333ZA Leiden, The Netherlands (L.D., M.J.B.T.); Department of Neurology, VU Medical Center, de Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands (J.C.R.); Amsterdam Medical Center, Department of Neurology, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands (J.C.R.); Department of Neuro-oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands (M.J.v.d.B.).
Esther J J HabetsMedical Center Haaglanden, Department of Neurology, Lijnbaan 32, 2512 VK The Hague, PO BOX 432, 2501 CK, The Hague, The Netherlands (H.Z., E.J.J.H., M.J.V., M.J.B.T.); Medical Center Haaglanden, Landsteiner Institute, Lijnbaan 32, 2512 VK The Hague, PO BOX 432, 2501 CK, The Hague, The Netherlands (T.V.); Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333ZA Leiden, The Netherlands (L.D., M.J.B.T.); Department of Neurology, VU Medical Center, de Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands (J.C.R.); Amsterdam Medical Center, Department of Neurology, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands (J.C.R.); Department of Neuro-oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands (M.J.v.d.B.).
Maaike J VosMedical Center Haaglanden, Department of Neurology, Lijnbaan 32, 2512 VK The Hague, PO BOX 432, 2501 CK, The Hague, The Netherlands (H.Z., E.J.J.H., M.J.V., M.J.B.T.); Medical Center Haaglanden, Landsteiner Institute, Lijnbaan 32, 2512 VK The Hague, PO BOX 432, 2501 CK, The Hague, The Netherlands (T.V.); Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333ZA Leiden, The Netherlands (L.D., M.J.B.T.); Department of Neurology, VU Medical Center, de Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands (J.C.R.); Amsterdam Medical Center, Department of Neurology, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands (J.C.R.); Department of Neuro-oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands (M.J.v.d.B.).
Jaap C ReijneveldMedical Center Haaglanden, Department of Neurology, Lijnbaan 32, 2512 VK The Hague, PO BOX 432, 2501 CK, The Hague, The Netherlands (H.Z., E.J.J.H., M.J.V., M.J.B.T.); Medical Center Haaglanden, Landsteiner Institute, Lijnbaan 32, 2512 VK The Hague, PO BOX 432, 2501 CK, The Hague, The Netherlands (T.V.); Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333ZA Leiden, The Netherlands (L.D., M.J.B.T.); Department of Neurology, VU Medical Center, de Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands (J.C.R.); Amsterdam Medical Center, Department of Neurology, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands (J.C.R.); Department of Neuro-oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands (M.J.v.d.B.).
Martin J van den BentMedical Center Haaglanden, Department of Neurology, Lijnbaan 32, 2512 VK The Hague, PO BOX 432, 2501 CK, The Hague, The Netherlands (H.Z., E.J.J.H., M.J.V., M.J.B.T.); Medical Center Haaglanden, Landsteiner Institute, Lijnbaan 32, 2512 VK The Hague, PO BOX 432, 2501 CK, The Hague, The Netherlands (T.V.); Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333ZA Leiden, The Netherlands (L.D., M.J.B.T.); Department of Neurology, VU Medical Center, de Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands (J.C.R.); Amsterdam Medical Center, Department of Neurology, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands (J.C.R.); Department of Neuro-oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands (M.J.v.d.B.).
Martin J B TaphoornMedical Center Haaglanden, Department of Neurology, Lijnbaan 32, 2512 VK The Hague, PO BOX 432, 2501 CK, The Hague, The Netherlands (H.Z., E.J.J.H., M.J.V., M.J.B.T.); Medical Center Haaglanden, Landsteiner Institute, Lijnbaan 32, 2512 VK The Hague, PO BOX 432, 2501 CK, The Hague, The Netherlands (T.V.); Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333ZA Leiden, The Netherlands (L.D., M.J.B.T.); Department of Neurology, VU Medical Center, de Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands (J.C.R.); Amsterdam Medical Center, Department of Neurology, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands (J.C.R.); Department of Neuro-oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands (M.J.v.d.B.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGliomas are rare, with a dismal outcome and an obvious impact on quality of life, because of neurological, physical and cognitive problems, as well as personality and behavioral changes. These latter changes may affect the lives of both patients and their relatives in a profound way, but it is unclear how often this occurs and to what extent.

methodsWe performed a systematic review to determine the prevalence of changes in personality and behavior in glioma patients. Searches were conducted in PubMed/Medline, PsycINFO, Cochrane, CINAHL and Embase. Based on predetermined in- and exclusion criteria, papers were screened for eligibility. Information on the topics of interest were extracted from the full-text papers.

resultsThe search yielded 9895 papers, of which 18 were found to be eligible; 9 qualitative and 9 quantitative studies. The reported prevalence rates of changes in personality and/or behavior varied from 8%-67% in glioma patients, and was 100% in a case series with bilateral gliomas. Moreover, these changes were associated with distress and a lower quality of life of patients as well as informal caregivers. Methods of measurement of personality and behavioral changes differed considerably, as did the description of these changes.

conclusionTo determine the true prevalence of changes in behavior and personality, present but poorly labeled in the reported studies, prospective studies are needed using proper definitions of personality and behavioral changes and validated measurement tools. Ultimately, these findings may result in improved supportive care of both patients and caregivers, during the disease trajectory.

Indexed as

behavior changebrain tumorgliomapersonality changeprevalence

Identifiers

PMID31386058
PMCPMC6657393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.